Beckman Coulter plans to issue convertibles to help fund $1.55 billion Biosite acquisition

By Angela McDaniels

Seattle, April 2 - Beckman Coulter, Inc. expects that about half of the permanent financing for its proposed acquisition of Biosite Inc. will consist of convertible notes, according to a company news release.

The remainder will be comprised of straight debt.

The company announced on March 25 that it entered into a definitive merger agreement to acquire all of Biosite's outstanding common stock in a cash tender offer of $85.00 per share, or about $1.55 billion.

Financing for the transaction has been fully committed by Morgan Stanley and Citigroup, according to the release.

Further details about the permanent financing will be provided following the close of the cash tender offer, which is expected to occur in the second quarter.

Beckman Coulter is based in Fullerton, Calif., and develops products used to automate biomedical tests.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.